Takeda Group's Gammagard (Notice of Intent to Sole Source)
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NATIONAL INSTITUTES OF HEALTH - CC
Contract Value
Not provided
Codes & Classification
Solicitation Number
NOI-27-000636
NAICS
-
Classification Code
6505
Additional Details
This presolicitation notice announces the National Institutes of Health (NIH) Clinical Center’s intent to negotiate a sole source procurement with Takeda Pharmaceutical Company Limited for the supply of Gammagard S/D kits. The NIH Clinical Center, located in Maryland, serves as a clinical research hospital dedicated to providing comprehensive medical services to patients enrolled in human research protocols. The Clinical Center’s Pharmacy Department is responsible for ensuring the continuous availability of essential medications required for patient care, particularly for those participating in ongoing clinical trials.
The scope of this procurement encompasses the acquisition of Gammagard S/D 10gm and Gammagard S/D 5gm kits, specifically requesting an initial purchase of 10 bottles of each kit, with additional quantities to be procured as needed to meet anticipated patient care demands. Gammagard S/D is a critical medication on the Clinical Center’s formulary, and its consistent availability is necessary to maintain uninterrupted therapy for current and future patients. The product is used in the treatment of multiple patients currently under care at the NIH, and the potential for additional patients to be transferred for evaluation and treatment further underscores the need for a reliable supply.
The justification for this sole source procurement is based on Takeda Group’s status as the only responsible source for Gammagard S/D. Continuity of care is paramount, and the NIH Clinical Center requires the use of the same product to ensure treatment consistency and patient safety. No set-aside requirements apply to this procurement, and it is not subject to competition due to the unique nature of the product and its critical role in patient care.
This notice is issued by the National Institutes of Health - Clinical Center (NIH-CC), a federal office under the Department of Health and Human Services. The procurement is classified under Product Service Code 6505 (Drugs and Biologicals), with the place of performance designated as Maryland, United States. Interested parties should note that this is a Notice of Intent and not a request for proposal; responses are due by November 16, 2026.
For further information or to express interest, the primary point of contact is Lu Chang, who can be reached via email at [email protected]. Additional details and updates regarding this opportunity can be found on the official SAM.gov listing at https://sam.gov/opp/e8d1758f73144ccdb7d0c14cb190f76b/view.
Contractors considering this opportunity should recognize that the requirement is highly specific, with a focus on maintaining continuity of care for NIH Clinical Center patients through the exclusive use of Gammagard S/D supplied by Takeda. The procurement process will remain consistent throughout the contract lifecycle, emphasizing the ongoing need for timely and reliable delivery of this essential medication.